These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry. Srivastava D Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015 [No Abstract] [Full Text] [Related]
3. US biosimilar pathway unlikely to be used: developers will opt for a traditional BLA filing. Wiatr C BioDrugs; 2011 Feb; 25(1):63-7. PubMed ID: 21222498 [TBL] [Abstract][Full Text] [Related]
4. Assessing the safety and comparative effectiveness of follow-on biologics (biosimilars) in the United States. Hennessy S; Leonard CE; Platt R Clin Pharmacol Ther; 2010 Feb; 87(2):157-9. PubMed ID: 20107450 [TBL] [Abstract][Full Text] [Related]
5. The comparability conundrum: biosimilars in the United States, Europe and Canada. Courage N; Parsons A Food Drug Law J; 2011; 66(2):203-24, i-ii. PubMed ID: 24505840 [TBL] [Abstract][Full Text] [Related]
6. Business of biosimilars - 14th annual conference (October 15-17, 2013 - Boston, Massachusetts, USA). Bourgoin A Drugs Today (Barc); 2013 Dec; 49(12):799-801. PubMed ID: 24524098 [TBL] [Abstract][Full Text] [Related]
7. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference. Crespi-Lofton J; Skelton JB J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708 [TBL] [Abstract][Full Text] [Related]
11. Insights of biosimilars through SWOT analysis. Patel MM; Shah PJ; Patel BM Expert Opin Biol Ther; 2014 Feb; 14(2):139-44. PubMed ID: 24151903 [No Abstract] [Full Text] [Related]
12. Biosimilars and the European experience: implications for the United States. Megerlin F; Lopert R; Taymor K; Trouvin JH Health Aff (Millwood); 2013 Oct; 32(10):1803-10. PubMed ID: 24101072 [TBL] [Abstract][Full Text] [Related]
13. The "reverse payment paradox": an overview of the legality of reverse exclusionary payments in the pharmaceutical industry. Brockmeier MS Health Care Law Mon; 2010 Mar; 2010(3):2-10. PubMed ID: 20329564 [No Abstract] [Full Text] [Related]
15. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers. Falit BP; Singh SC; Brennan TA Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110 [TBL] [Abstract][Full Text] [Related]
16. Biosimilars: State of Clinical and Regulatory Science. Klein AV; Wang J; Feagan BG; Omoto M J Pharm Pharm Sci; 2017; 20(1):332-348. PubMed ID: 29145936 [TBL] [Abstract][Full Text] [Related]
17. The Tortoise and the Hare: Evolving Regulatory Landscapes for Biosimilars. Konara CS; Barnard RT; Hine D; Siegel E; Ferro V Trends Biotechnol; 2016 Jan; 34(1):70-83. PubMed ID: 26620970 [TBL] [Abstract][Full Text] [Related]
18. Current issues in the pioneer versus generic drug wars. Safir PO Food Drug Law J; 1995; 50(2):335-9. PubMed ID: 10343002 [No Abstract] [Full Text] [Related]
19. World Generic Medicines Congress Americas--a Health Network Communications Conference. 18-21 November 2008, Washington DC, USA. Bowman M IDrugs; 2009 Feb; 12(2):92-4. PubMed ID: 19204881 [No Abstract] [Full Text] [Related]
20. An unofficial legislative history of the Biologics Price Competition and Innovation Act of 2009. Carver KH; Elikan J; Lietzan E Food Drug Law J; 2010; 65(4):671-818, ii. PubMed ID: 24479247 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]